

@article {3599,
	title = {Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond.},
	journal = {Clinical Infectious Diseases},
	volume = {45},
	number = {12},
	year = {2007},
	pages = {1618{\textendash}1624},
	abstract = {<p>Twenty-five years passed between the discovery of the parent strain \{\{\}(WC3)\{\}\} of the pentavalent human-bovine reassortant rotavirus vaccine \{\{\}(PRV)\{\}\} in 1981 and the licensure of \{\{\}PRV\{\}\} in 2006. This orally administered liquid vaccine, which is given as a 3-dose series, is indicated for the prevention of rotavirus gastroenteritis, caused by the G serotypes contained in the vaccine, in infants and children. \{\{\}PRV\{\}\} is recommended by the Advisory Committee on Immunization Practices and the American Academy of Pediatrics for administration to all infants in the United States. These recommendations are supported by the results of the phase \{\{\.I}II\{\}\} studies, which demonstrated that \{\{\}PRV\{\}\} is well tolerated and efficacious. \{\{\}PRV\{\}\} reduced rotavirus-related hospitalizations by 96\{\%\} and was not associated with an increased incidence of serious adverse events, including intussusception. This report focuses on the safety and efficacy data from the late-phase studies of \{\{\}PRV\{\}\} and discusses plans for providing this vaccine to the developing world.</p>
},
	doi = {10.1086/522997},
	url = {http://dx.doi.org/10.1086/522997},
	author = {Heaton, Penny M and Ciarlet, Max}
}
